Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Erlotinib for Patients With Malignant Peritoneal Mesothelioma (MPeM) Exhibiting EGFR Mutations

NCT01592383 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT01592383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01592383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Erlotinib for Patients With Malignant Peritoneal Mesothelioma (MPeM) Exhibiting EGFR Mutations
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2012
Completion date
February 28, 2017
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant peritoneal mesothelioma